The FDA has granted breakthrough device designation for an implantable insulin pump designed for people with type 1 diabetes, according to an industry press release. The implantable device (Portal ...
Targeted MAPK pathway inhibition with atebimetinib contrasts with nonselective cytotoxic chemotherapy and is paired with a dose-schedule modification intended to ...
Mark Gurarie is a writer covering health topics, technology, music, books, and culture. He also teaches health science and research writing at George Washington University's School of Medical and ...